Higher CD56+or CD2+lymphocyte percentage predicts poor steroid response in patients with immune thrombocytopenia

被引:4
|
作者
Wu, Yi-Feng [1 ]
Huang, Wei-Han [1 ,2 ]
Gu, Ming-Huei [3 ]
Lin, Siao-Ru [3 ]
Chu, Sung-Chao [1 ,4 ]
Wang, Tso-Fu [1 ,4 ]
Li, Chi-Cheng [1 ,5 ]
机构
[1] Hualien Tzu Chi Hosp, Dept Hematol & Oncol, Buddhist Tzu Chi Med Fdn, 707,Sec 3,Chung Yang Rd, Hualien 970, Taiwan
[2] Hualien Tzu Chi Hosp, Dept Clin Pathol, Buddhist Tzu Chi Med Fdn, 707,Sec 3,Chung Yang Rd, Hualien 970, Taiwan
[3] Hualien Tzu Chi Hosp, Dept Lab Med, Buddhist Tzu Chi Med Fdn, 707,Sec 3,Chung Yang Rd, Hualien 970, Taiwan
[4] Tzu Chi Univ, Coll Med, 707,Sec 3,Chung Yang Rd, Hualien 970, Taiwan
[5] Hualien Tzu Chi Hosp, Ctr Stem Cell & Precis Med, Tzu Chi Med Fdn, 707,Sec 3,Chung Yang Rd, Hualien 970, Taiwan
关键词
Immune thrombocytopenia; Steroid response; Lymphocyte subgroup; Flow cytometry; ADHESION PROTEIN CD2; MEDIATED CYTOTOXICITY; STRUCTURAL BIOLOGY; PURPURA; CELLS; CHILDREN; ADULTS;
D O I
10.1016/j.thromres.2019.10.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Immune thrombocytopenia (ITP) is known as an immune-mediated disease and often evolves to chronic type in adult. Corticosteroids only work in around 60% of patients. This study evaluated the roles of subgroup lymphocytes from peripheral blood in ITP adults with different treatment response. Methods: Between October 2009 and March 2017, 37 adults were newly diagnosed as ITP requiring treatment. The patients were separated into two groups: 23 patients with platelet count < 50,000/mu L with corticosteroid dependence or second-line treatment (Poor-responder Group), and 14 patients with platelet counts < 50,000/mu L with standard steroid treatment, which stopped within three months (Good-responder Group). Subgroup lymphocyte percentages of peripheral blood were determined through flow cytometry before treatment. Data analysis with Mann-Whitney test and receiver operating characteristic curves were performed using GraphPad Prism (Version 7). A p-value of < 0.05 was considered significant. Results: Lymphocyte percentage was significantly lower in Poor-responder Group than in Good-responder Group (p = 0.008). In subgroup lymphocytes, higher percentages of CD19+ B lymphocytes were found in Good-responder Group (p = 0.03). In Poor-responder Group, a higher CD2+ and CD56+ lymphocytes were observed (p = 0.02 and 0.03). By the cut-off value of percentage of CD56+ lymphocytes with 24.5% or CD2+ lymphocytes with 85.7%, the specificity showed 92.86%. Conclusions: This study found that newly diagnosed ITP patients with increased percentages of CD56+ or CD2+ lymphocytes in peripheral blood associated with a poorer response to steroid treatment.
引用
收藏
页码:63 / 68
页数:6
相关论文
共 50 条
  • [41] Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m62A and CD) regulations on patients with cancer and healthy individuals
    Du, Jiaman
    Fu, Jiewen
    Zhang, Wenqian
    Zhang, Lianmei
    Chen, Hanchun
    Cheng, Jingliang
    He, Tao
    Fu, Junjiang
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2023, 62 (03)
  • [42] URINARY CD163 PREDICTS COMPLETE RENAL RESPONSE WITH ZETOMIPZOMIB TREATMENT IN THE OPEN-LABEL MISSION PHASE 2 STUDY IN PATIENTS WITH LUPUS NEPHRITIS
    Merrill, J. T.
    Leff, R.
    Fan, A.
    Palaniswamy, K.
    Henig, N.
    Hua, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 901 - 901
  • [43] HIGHER PRETREATMENT HCV-SPECIFIC CD4+AND CD8+T CELLS IN PATIENTS WITH A RAPID VIROLOGICAL RESPONSE AFTER PEGINTERFERON-ALPHA-2A/RIBAVIRIN THERAPY BUT NOT AT WEEK 12 OF THERAPY
    Arends, J. E.
    Nanlohy, N. M.
    Hoepelman, I. M.
    van Baarle, D.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S316 - S316
  • [44] The Humoral Immune Response to BNT162b2 Vaccine Is Associated With Circulating CD19+B Lymphocytes and the Naive CD45RA to Memory CD45RO CD4+T Helper Cells Ratio in Hemodialysis Patients and Kidney Transplant Recipients
    Duni, Anila
    Markopoulos, Georgios S.
    Mallioras, Ioannis
    Pappas, Haralampos
    Pappas, Efthymios
    Koutlas, Vasileios
    Tzalavra, Eirini
    Baxevanos, Gerasimos
    Priska, Silvia
    Gartzonika, Konstantina
    Mitsis, Michael
    Dounousi, Evangelia
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [45] Reciprocal role of hBD2 and hBD3 on the adaptive immune response by measuring T lymphocyte proliferation in terms of CD4 and CCR6 expression
    Taefehshokr, Nima
    Isazadeh, Alireza
    Oveisi, Amin
    Key, Yashar Azari
    Taefehshokr, Sina
    HORMONE MOLECULAR BIOLOGY AND CLINICAL INVESTIGATION, 2018, 35 (03)
  • [46] Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study
    Xu, Min
    Shu, Jinhui
    Qian, Shenxian
    Guo, Jingming
    Gong, Yuping
    Huang, Ruibin
    Wang, Shuye
    Zhou, Zeping
    Yuan, Guolin
    Huang, Meijuan
    Lin, Li -E
    Lou, Shifeng
    Song, Yanping
    Liu, Qingchi
    Zhou, Hu
    Mei, Heng
    Hu, Yu
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 47
  • [47] The cellular and humoral Immune Response after SARS-CoV-2 Vaccination in Patients after CD19.CAR-T Cell Therapy
    Kessler, A.
    Drexel, H.
    Dertinger, S.
    Dirnhofer, S.
    Hoffmann, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 45 - 45
  • [48] NKG2A+CD56dimCD16br NK cell subset as a potential prognostic marker of response to benralizumab treatment in severe eosinophilic asthmatic patients.
    Bergantini, Laura
    D'Alessandro, Miriana
    Pianigiani, Tommaso
    Bargagli, Elena
    Cameli, Paolo
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [49] Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis
    Sheridan, James P.
    Zhang, Ying
    Riester, Katherine
    Tang, Meina T.
    Efros, Lyubov
    Shi, Jia
    Harris, Jeffrey
    Vexler, Vladimir
    Elkins, Jacob S.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (12) : 1441 - 1448
  • [50] Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
    Louapre, Celine
    Ibrahim, Michella
    Maillart, Elisabeth
    Abdi, Basma
    Papeix, Caroline
    Stankoff, Bruno
    Dubessy, Anne-Laure
    Bensa-Koscher, Caroline
    Creange, Alain
    Chamekh, Zina
    Lubetzki, Catherine
    Marcelin, Anne-Genevieve
    Corvol, Jean-Christophe
    Pourcher, Valerie
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (01): : 24 - 31